Therapy of systemic sclerosis;La terapia della sclerosi sistemica

Reumatismo

Volumn 56, Issue 1, 2004, Pages 1-8

  Valentini, Gabriele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Disease modifying drugs; Outcome criteria; Symtomatic drugs; Systemic sclerosis

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALPHA INTERFERON; BOSENTAN; CALCIUM ANTAGONIST; CORTISONE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; INFLIXIMAB; PREDNISOLONE; PROSTACYCLIN; PROTON PUMP INHIBITOR; RELAXIN;

ACHIEVEMENT; CLINICAL RESEARCH; DRUG ACTIVITY; HEALTH CARE PLANNING; HUMAN; LUNG ALVEOLITIS; METHODOLOGY; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; SYSTEMIC SCLEROSIS;

HUMANS; SCLERODERMA, SYSTEMIC;

EID: 1942504920     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Valentini G. Trattamento della Sclerosi Sistemica. Reumatismo 1992; 44: 259-64.
2. Seibold JR, Furst DE, Clements PJ. Why everything (or nothing) seems to work in the treatment of Scleroderma. J Rheumatol 1992; 19: 673-6.
3. Torres MA, Furst DE. Treatment of generalized systemic sclerosis. Rheum Dis Clin Ann 1990; 16: 217-41.
4. Le Roy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA et al. Scleroderma (Systemic Sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
5. White B, Bauer EA, Goldsmith LA, Heald PW, Hoeberg MC, Katy LM et al. Guidelines for Clinical trials in Systemic Sclerosis 1. Disease modifying interventions. Arthritis Rheum 1995; 38: 351-60.
6. Medsger TA Jr. Natural history of Systemic Sclerosis and the assessment of disease activity, severity, functional status and psychologic well being. Rheum Dis Clin N Ann 2003; 29: 255-73.
7. Boers M, Brooks P, Strand V, Tugwell P. The OMERACT filter for outcome measures in Rheumatology. J Rheumatol 1998; 25: 198-9.
8. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F et al. High-dose versus low-dose D-penicillamine in early diffuse Systemic Sclerosis. Analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999; 42: 1194-203.
9. Steen VD, Medsger TA Jr, Rodnan GP. D. Penicillamine therapy in progressive systemic sclerosis. A retrospective analysis. Ann Int Med 1982; 97: 652-9.
10. Jimeney SA, Sigal SH. A 15-years prospective study of rapidly progressive Systemic Sclerosis with D-Penicillamine. J Rheumatol 1991; 18: 1496-503.
11. Black CM, Silman AJ, Herrick AI, Denton CP, Wilson H, Newman J et al. Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma. Arthritis Rheum 1999; 42: 399-405.
12. Seibold JR, Clements PS, Korn JH. Phase III trial of relaxin in diffuse scleroderma. J Rheumatol 2001; 28: (suppl 63): 55.
13. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines: Guidelines for the management of Rheumatoid Arthritis. 2002 update. Arthritis Rheum 2002; 46: 328-48.
14. Merkel PA, Clements PJ, Reveille JD, Suarez Almazor ME, Valentini G, Furst DE. Current status of outcome measures development for clinical trials in Systemic Sclerosis. Report from OMERACT 6. J Rheumatol 2003; 30: 1630-47.
15. Clements PJ, Huwitz EL, Wong WK, Seibold JR, Mayes M, White B et al. Skin thickness score is a predictor and correlate of outcomein systemic sclerosis: the high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000; 43: 2445-54.
16. Steen VD, Medsger TA Jr. Improvement in skin thickening in Systemic Sclerosis associated with improved survival. Arthritis Rheum 2001; 44: 2828-35.
17. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient generated scales to demonstrate change in Systemic Sclerosis patients over time. Arthritis Rheum 1997; 40: 1984-91.
18. Clements PJ, Wong WK, Huwitz EL, Furst DE, Mayes M, White B et al. The disability index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in Systemic Sclerosis trial. Arthritis Rheum 2001; 44: 653-61.
19. Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002; 46: 2410-20.
20. Medsger TA Jr, Silman AJ, Sheen VD, Black CM, Akesson A, Bacon PA et al. A disease severity scale for Systemic Sclerosis: development and testing. J Rheumatol 1999; 26: 2959-67.
21. Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman A, D'Angelo S. European multicentre study to define disease activity criteria for Systemic Sclerosis II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001; 60: 592-8.
22. Seibold JR. Clinical trials: types, design and end points. Curr Opin Rheumatol 2001; 13: 512-5.
23. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G et al. Systemic Sclerosis. Demographic, clinical and serologic features and survival in 1,012 Italian patients. Medicine 2002; 81: 139-53.
24. Furst DE. Rational therapy in the treatment of Systemic Sclerosis. Curr Opin Rheumatol 2000; 12: 540-4.
25. Wigley FH, Wise RA, Seibold JR, McCloskey DA, Krujela G, Medsger TA et al. Intravenous iloprost infusion in patients with Raynaud's phenomenon secondary to Systemic Sclerosis. A multicentre, placebo controlled, double-blind study. Ann Intern Med 1994; 120: 199-206.
26. Scorza R, Caronni M, Mascagni B, Berzuti V, Bazzi S, Micalle E et al. Effect of long-term cyclic iloprost therapy in Systemic Sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin Exp Rheumatol 2001; 19: 503-8.
27. Humbert M, Cabane J. Successful treatment of Systemic Sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology 2003; 42: 191-3.
28. Sambo P, Amico D, Giacomelli R, Matucci Cerinic M, Salsano F, Valentini G et al. Intravenous N-acetylcysteine for tratment of Raynaud's phenomenon secondary to Systemic Sclerosis. A pilot study. J Rheumatol 2001; 28: 2257-62.
29. Menon Y, Cucurull E, Espinoza LR. Pancytopenia in a patient with scleroderma treted with infliximab. Rheumatology 2003; 42: 1273-4.
30. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Inter Med 2000; 132: 947-54.
31. Giacomelli R Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in Systemic Sclerosis. J Rheumatol 2002; 29: 731-6.
32. Badasch DB, Tapson VF, Mc Goon MD, Brundege BH, Hubin LJ Wigley FM et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med 2000; 132: 425-34.
33. Rubin LJ, Badesh DO, Barst RJ, Golià N. Bosentan therapy for pulmonary arterial hypertension N Engl J Med 2002; 346: 896-903.
34. Rosenkranz S, Diet F, Karasch T, Weihrauch J, Wassermann K, Erdmann E. Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and Raynaud's phenomenon. Ann Intern Med 2003; 139: 871-3.
35. Launay D, Hachulla E, Hatron PY, Goullard L, Onimus T, Robin S et al. Aerosolized iloprost in CREST syndrome related pulmonary hypertension. J Rheumatol 2001; 28: 2252-6.
36. Kenefick NJ, Vaizey CJ, Nicholls RJ, Cohen R, Kamm MA. Sacral nerve stimulation for faecal incontinence due Systemic Sclerosis. Gut 2002; 51: 881-3.
37. Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C et al. Phase I/II trial and antologous sten cell transplantatio in Systemic Sclerosis: procedure related normality and impact on skin disease. Ann Rheum Dis 2001; 60: 577-84.
38. Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Kiraz S, Ozturk MA, Celik I. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol 2003; 22: 289-91.
39. Apras S, Ertenli I, Ozbalkan Z, Kiraz S, Ozturk MA, Haznedaroglu IC et al. Effect of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse Systemic Sclerosis. Arthritis Rheum 2003; 63: 171-4.
40. Lin A.TH, Clements PJ, Furst De. Update on disease modifying antistaminic drugs in the treatment of Systemic Sclerosis. Rheum Dis Clin N Ann 2003; 29: 409-26.